Omega Diagnostics Share Discussion Threads

[tickboo] 05/5/2017 14:40

Anther 8,888 snapped up to take me to 88,888, lucky numbers!

[dibs61] 05/5/2017 13:51

Agreed.

But why 30p? Is there a technical factor there?

[longshanks] 05/5/2017 13:44

I am sure Mr Sneller hasn't finished buying yet. Still plenty of value to unfold and the stock is starting to become attractive to momentum investors. When we break 30p this really will fly.

[dibs61] 05/5/2017 12:57

Possibly both? But my guess is simple demand exceeding available supply. Which is one reason why I think a one off fundraising would be extremely successful here and would actually be a share price catalyst. Strengthen the BS in advance of Visitect CD4 roll out.

But whatever happens the future here looks quite exciting to say the least.

[barrywhit] 05/5/2017 12:38

Blimey, looking good lads......News Monday???....or just no stock around??

[hyperboreus] 04/5/2017 16:30

Maybe not! 😂

[hyperboreus] 04/5/2017 16:18

MM's short of stock again, only able to buy 1000 @23.75p at the moment

[dibs61] 04/5/2017 15:40

Moving north again

[rivaldo] 03/5/2017 09:28

New report on ODX from Hardman FYI (free to view):



On top of the core business earning 1p+ EPS, there are now 3 areas which could be transformational:

- Allersys
- CD4
- malaria

I'm also extremely keen on the Food Intolerance tests - 56% of sales - which will imo bring in consistently rising sales for many years to come. This is particularly so with expansion to the USA - for example, coeliac disease awareness/testing in the USA in general is well behind that in the UK.

[rivaldo] 26/4/2017 08:27

Finncap have introduced a forecast of 1.3p EPS for the current year to March'18. As I posted previously they have a 28p target price, in line with sector comparables of a FY2017 EV/Sales of 1.9 times.

Encouragingly they say they expect upgrades, further to the outcome of the IDH discussions

"We have excluded any revenues from our FY 2018 forecasts pending clarification of the outcome of discussions, although we expect to see upgrades during the year"

They also note they expect CD4 "to be CE-marked with a launch likely in late calendar 2017", so not long to wait assuming the field trials go smoothly.

[barrywhit] 25/4/2017 16:33

Ah well, we nearly held on to our gains of the last week, lets hope all the short term traders have left the building..........perhaps we will settle into a new trading range 21 - 25p....

[leedslad001] 25/4/2017 12:24

Morning all, looking good all positive upwards and onwards over next few years

[rivaldo] 25/4/2017 08:48

Finncap have retained their 28p price target for the moment.

Today's was a perfectly good trading update in every way - profits nicely in line, CD$ progressing well and Allersys and allergens also advancing.

It's also good to see the Indian production facility going so smoothly - there were a lot of factors which could have gone wrong. The malaria test should be a big winner in the months and years ahead, whilst Food Intolerance will only continue to grow.

There should be further news flow to come on the IDH tie-up and CD4 progress. I can see that there was no single catalyst in today's statement to keep the short-termers interested, but over time there's certainly the prospect of a multibagger from here imho.

[barrywhit] 25/4/2017 08:15

Here come all the shares bought in the last few weeks, most making a penny a share, you have to laugh, NOT A TRADING SHARE......

[jeevsje] 25/4/2017 07:58

You won't get the chance to hold for years. Mark my words - this will be sold at roughly 2X to 3X of current share price once CD4 is commercialised.

[barrywhit] 25/4/2017 07:58

If we can hold the existing rise I will be happy.....3 years is about right p1nkfish...

[p1nkfish] 25/4/2017 07:53

Good to see growth in constant currency terms even if only 3%, it's v. good.
Malaria, could be massive.
Strong Hold for more than a few months. 3 yrs more like.

[tickboo] 25/4/2017 07:42

A decent RNS and once cd4 is commercialised the share price will be multiples of here and they'll be more cash to develop new products. Am long. Shame I've only got 75,000 but will get some more in the coming weeks ahead of the FY results.

[shanklin] 25/4/2017 07:41

Blimey, anything for a quiet life, but I am hoping for rather more than 30p in due course :-)

[dibs61] 25/4/2017 07:40

Very encouraging update. Two notables for me are significantly increased pre tax profit and a formal design freeze on CD4 so we move into verification phase. Getting tantalisingly close to CE marking submission.

No further change on IDH but I trust the company to get it right.

No stock out there so any demand will push share price further north + RS factor ;)

No reason why share price should not continue to appreciate

[jeevsje] 25/4/2017 07:33

Not selling, Long. On the contrary, I am putting couple of fill or kill orders at 26p. I will be keeping you guys company until at least a few months when we will all go our own ways.

[longshanks] 25/4/2017 07:27

Hopefully we will see 30, you will sell and this BB can be saved any more inane chatter

[barrywhit] 25/4/2017 07:26

All makes good reading to me....

[jeevsje] 25/4/2017 07:08

Can see 30s in coming days:

Allergy development
IDS-iSYS automation update
We continue to have discussions with IDS on how best to commercialise our Allersys® range of reagents and believe we can achieve an outcome that will benefit both parties. The time taken on the discussions to date reflects the importance on achieving the right balance for both parties on what we anticipate will be a long term relationship. We will provide a further update in due course.

We have continued to develop the allergen range and we have now optimised a further nine allergens, in addition to the 41 allergens which are CE-Marked for use on the IDS-iSYS automated instrument.

Infectious disease
CD4 update
We confirm we have now attained formal design freeze with our VISITECT® CD4 test following the successful manufacture of three pilot batches. Devices from these batches were tested at three UK hospital sites, on sufficient numbers of patient samples to demonstrate that we now have a method for manufacturing devices which consistently meet our design goal specifications regarding sensitivity and specificity.

Achieving this significant milestone means we have now progressed into the formal verification and validation phase. We will use the chosen design to manufacture three validation batches which will be sent for field trial evaluation at selected sites in the UK and India. The field trial results, combined with a number of planned internal experiments to support product claims will, if successful, enable us to CE-Mark the test after conclusion of these activities.

Outlook
We have reached a significant milestone in achieving design freeze with our VISITECT® CD4 development programme. We remain confident in completing the verification and validation programme to deliver a unique product which we believe will meet a large unmet medical need for people living with HIV infections in resource-limited countries.

We have also been successful in achieving full operational capability with our manufacturing facility in Pune, India. Whilst we have already indicated we expect to achieve modest sales with our Malaria range of tests this year, we believe we have created a valuable asset which can grow shareholder value in the years ahead.

We are encouraged by the ongoing performance of our core business. Our Food Intolerance division continues to grow at a healthy rate and we are reviewing initiatives as to how we may grow this business in North America. Our allergy business in Germany achieved a 3% increase in euro denominated turnover, reversing a declining trend in recent years. The development updates we have outlined and the investments we have made in people and infrastructure give us much confidence for the future.